Health Stocks in Motion
Updated from 2:11 p.m. EDT
Shares of Forbes Medi-Tech (FMTI) were among the best-performing health and pharmaceutical stocks Wednesday after the company announced a three-year supply agreement with an unidentified customer.
The $24.4 million sales contract is scheduled to begin in January 2005 and will involve the company's Phyto-Source unit and a leading multinational ingredient company. The biopharmaceutical company said the supply agreement would allow it to expand its phytosterol business and allow it to possibly increase production capabilities. Shares of Forbes Medi-Tech traded up 49 cents, or 26.3%, to $2.35.
Nymox Pharmaceutical (NYMX) rose after it announced positive one-year prostrate drug trial results. The results from its phase II testing of NX-1207, a drug used to treat benign prostatic hyperplasia, showed symptomatic improvement in individuals treated with the drug. The company termed the improvement statistically significant. What's more, there were no significant adverse side effects during the trials. Benign prostatic hyperplasia affects about 50% of men over the age of 50 and close to 90% of men by the age of 80. Shares traded up 9 cents, or 3.9%, to $2.43.Shares of McKesson (MCK) fell after the company warned that it would miss second-quarter earnings estimates. The drug wholesaler now expects to earn between 75 cents and 80 cents a share during the first half of the year. The company earned 53 cents a share during the first quarter, which would imply second quarter earnings of 22 cents to 27 cents a share. Analysts polled by Thomson First Call were expecting second-quarter earnings of 50 cents a share. Looking ahead, McKesson reaffirmed its full-year earnings estimate of $2.20 to $2.35. Analysts are expecting earnings of $2.20 a share. Shares of McKesson traded down $4.85, or 15.2%, to $26.98. Third Wave Technologies (TWTI) rose after the company announced that TriCore Reference Laboratories selected its Invader hepatitis C virus genotyping reagents for use in TriCore laboratories. The product, which was selected by TriCore after a head-to-head comparison of competing products, is being used by TriCore to develop assays that identify all six genotypes of the hepatitis C virus. Shares of Third Wave Technologies traded up 47 cents, to 8%, to $6.36.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV